Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617

Clin Nucl Med. 2016 Jul;41(7):572-3. doi: 10.1097/RLU.0000000000001200.

Abstract

An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Dipeptides / therapeutic use*
  • Heterocyclic Compounds, 1-Ring / therapeutic use*
  • Humans
  • Lutetium / therapeutic use*
  • Male
  • Neoplasm Metastasis
  • Positron Emission Tomography Computed Tomography
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
  • Prostatic Neoplasms, Castration-Resistant / pathology*
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy*
  • Radioisotopes*
  • Treatment Outcome

Substances

  • Dipeptides
  • Heterocyclic Compounds, 1-Ring
  • PSMA-617
  • Radioisotopes
  • Lutetium
  • Prostate-Specific Antigen